<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37650184</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0578-1426</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Zhonghua nei ke za zhi</Title><ISOAbbreviation>Zhonghua Nei Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Clinical characteristics of patients with rheumatic diseases and abnormal liver function].</ArticleTitle><Pagination><StartPage>1102</StartPage><EndPage>1113</EndPage><MedlinePgn>1102-1113</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112138-20220909-00669</ELocationID><Abstract><AbstractText><b>Objective:</b> To investigate the clinical characteristics of patients with rheumatic diseases and abnormal liver function, as well as determine the proportion and severity of liver function abnormalities. <b>Methods:</b> Cross-sectional study. Data were collected from patients registered in the Chinese Rheumatism Date Center from 2011 to 2021. The rheumatic diseases analyzed in this study were rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren syndrome (SS), ankylosing spondylitis (AS), and gout. Patient data, including demographic characteristics [ such as age, sex, body mass index,(BMI), and smoking history], liver function test results [including alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphatase(ALP), and total bilirubin], and use of anti-rheumatic immune drugs and liver-protective drugs, were collected and compared between groups with normal and abnormal liver functions. In addition, the proportions of abnormal liver function were compared between sex and age groups. <b>Results:</b> A total of 116 308 patients were included in this study, including 49 659 with RA, 17 597 with SLE, 9 039 with SS, 11 321 with AS, and 28 692 with gout. The lowest proportion of liver function abnormalities was observed in patients with RA[11.02% (5 470/49 659)], followed by those with SS[17.97% (1 624/9 039)] and AS [18.22% (2 063/11 321) ], whereas patients with SLE [21.14% (3 720/17 597) ] and gout [28.73% (8 242/28 692)] exhibited the highest proportion of these abnormalities. Elevated ALT, mostly classified as grade 1, was the most commonly noted liver function abnormality, whereas elevated ALP was the least common. Some patients who took liver-protective drugs had normal liver function, with the lowest percentage observed in patients with gout [7.45% (36/483) ] and ranging from 21.7% to 30.34% in patients with RA, SLE, SS, and AS. The proportion of liver function abnormalities was higher in males than in females for all disease types [RA: 13.8%(1 368/9 906) vs. 10.3%(4 102/39 753); SLE: 33.6% (479/1 424) vs. 20.0% (3 241/16 173); SS: 25.4%(111/437) vs. 17.6%(1 513/8 602); AS: 20.1%(1 629/8 119) vs. 13.6% (434/3 202); and gout: 29.3% (8 033/27 394) vs. 16.1% (209/1 298)]. In RA, SLE, and AS, the proportions of liver function abnormalities were similar across all age groups. In SS, the proportion of liver function abnormalities increased with age [&lt;40 years: 14.9%(294/1 979); 40-59 years: 18.1%(858/4 741); &#x2265;60 years: 20.4%(472/2 319)], whereas a reversal of this trend was observed in gout [&lt;40 years: 34.9%(4 294/12 320); 40-59 years: 25.5%(2 905/11 398);&#x2265;60 years: 21.0%(1 042/4 971)]. <b>Conclusions:</b> The proportions of combined liver function abnormalities in patients with rheumatologic diseases were high, and the utilization rates of liver-protective drugs were low. It is necessary to pay more attention to monitoring patients' liver function, timely administer liver-protective drugs, and optimize liver-protective regimens during the treatment of rheumatic diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>C Y</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital,Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital,Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>X W</ForeName><Initials>XW</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>H B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 028000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Q</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, the First People's Hospital of Yunnan Province, Kunming 650032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha 410008, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>L J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Rheumatoid Arthritis, Urumuqi 830001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y F</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, the First Affiliated Hospital of Baotou Medical College, Science and Technology University of Inner Mongolia, Baotou 014010, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Y F</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, the Southwest Hospital of Army Medical University, Chongqing 400038, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>S D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Hainan General Hospital, Haikou 570311, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital,Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>X P</ForeName><Initials>XP</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital,Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>M T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital,Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>X F</ForeName><Initials>XF</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital,Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021YFC2501301-5, 2019YFC0840603, 2017YFC0907601-3</GrantID><Agency>Chinese National Key Technology Research and Development Program, Ministry of Science and Technology</Agency><Country/></Grant><Grant><GrantID>Z201100005520022, Z201100005520023, Z201100005520025-27</GrantID><Agency>Beijing Municipal Science &amp; Technology Commission</Agency><Country/></Grant><Grant><GrantID>2021-I2M-1-005</GrantID><Agency>Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Nei Ke Za Zhi</MedlineTA><NlmUniqueID>16210490R</NlmUniqueID><ISSNLinking>0578-1426</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.1.3.1</RegistryNumber><NameOfSubstance UI="D000469">Alkaline Phosphatase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006073" MajorTopicYN="Y">Gout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013167" MajorTopicYN="Y">Spondylitis, Ankylosing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000469" MajorTopicYN="N">Alkaline Phosphatase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x76ee;&#x7684;&#xff1a;</b> &#x5206;&#x6790;&#x5e38;&#x89c1;&#x98ce;&#x6e7f;&#x514d;&#x75ab;&#x75c5;&#x60a3;&#x8005;&#x5408;&#x5e76;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x7684;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#x53ca;&#x4e25;&#x91cd;&#x7a0b;&#x5ea6;&#x3002; <b>&#x65b9;&#x6cd5;&#xff1a;</b> &#x6a2a;&#x65ad;&#x9762;&#x8c03;&#x67e5;&#x3002;&#x60a3;&#x8005;&#x6765;&#x81ea;2011&#x81f3;2021&#x5e74;&#x5728;&#x56fd;&#x5bb6;&#x98ce;&#x6e7f;&#x75c5;&#x8bca;&#x7597;&#x6570;&#x636e;&#x4e2d;&#x5fc3;&#xff08;CRDC&#xff09;&#x5e73;&#x53f0;&#x767b;&#x8bb0;&#x6ce8;&#x518c;&#x7684;&#x7c7b;&#x98ce;&#x6e7f;&#x5173;&#x8282;&#x708e;&#xff08;RA&#xff09;&#x3001;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#xff08;SLE&#xff09;&#x3001;&#x5e72;&#x71e5;&#x7efc;&#x5408;&#x5f81;&#xff08;SS&#xff09;&#x3001;&#x5f3a;&#x76f4;&#x6027;&#x810a;&#x67f1;&#x708e;&#xff08;AS&#xff09;&#x3001;&#x75db;&#x98ce;&#x60a3;&#x8005;&#x3002;&#x6536;&#x96c6;&#x60a3;&#x8005;&#x7684;&#x4e00;&#x822c;&#x4eba;&#x53e3;&#x5b66;&#x8d44;&#x6599;&#xff08;&#x5305;&#x62ec;&#x5e74;&#x9f84;&#x3001;&#x6027;&#x522b;&#x3001;&#x4f53;&#x91cd;&#x6307;&#x6570;&#x3001;&#x5438;&#x70df;&#x53f2;&#x7b49;&#xff09;&#x3001;&#x809d;&#x529f;&#x80fd;&#x68c0;&#x67e5;&#x7ed3;&#x679c;&#xff08;&#x5305;&#x62ec;&#x4e19;&#x6c28;&#x9178;&#x8f6c;&#x6c28;&#x9176;&#x3001;&#x5929;&#x51ac;&#x6c28;&#x9178;&#x8f6c;&#x6c28;&#x9176;&#x3001;&#x78b1;&#x6027;&#x78f7;&#x9178;&#x9176;&#x3001;&#x603b;&#x80c6;&#x7ea2;&#x7d20;&#x7b49;&#xff09;&#x3001;&#x6297;&#x98ce;&#x6e7f;&#x514d;&#x75ab;&#x836f;&#x7269;&#x548c;&#x4fdd;&#x809d;&#x836f;&#x7269;&#x7684;&#x4f7f;&#x7528;&#x60c5;&#x51b5;&#x3002;&#x5206;&#x6790;&#x60a3;&#x8005;&#x7684;&#x4e34;&#x5e8a;&#x7279;&#x5f81;&#x3001;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x7684;&#x6bd4;&#x4f8b;&#x3001;&#x4e0d;&#x540c;&#x6027;&#x522b;&#x548c;&#x5e74;&#x9f84;&#x6bb5;&#x7684;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x7387;&#x3002; <b>&#x7ed3;&#x679c;&#xff1a;</b> &#x5171;&#x7eb3;&#x5165;116 308&#x4f8b;&#x60a3;&#x8005;&#xff0c;&#x5176;&#x4e2d;RA&#x60a3;&#x8005;49 659&#x4f8b;&#xff0c;SLE&#x60a3;&#x8005;17 597&#x4f8b;&#xff0c;SS&#x60a3;&#x8005;9 039&#x4f8b;&#xff0c;AS&#x60a3;&#x8005;11 321&#x4f8b;&#xff0c;&#x75db;&#x98ce;&#x60a3;&#x8005;28 692&#x4f8b;&#x3002;RA&#x60a3;&#x8005;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x6bd4;&#x4f8b;&#x6700;&#x4f4e;&#xff3b;11.02%&#xff08;5 470/49 659&#xff09;&#xff3d;&#xff0c;&#x5176;&#x6b21;&#x662f;SS&#x60a3;&#x8005;&#xff3b;17.97%&#xff08;1 624/9 039&#xff09;&#xff3d;&#x548c;AS&#x60a3;&#x8005;&#xff3b;18.22%&#xff08;2 063/11 321&#xff09;&#xff3d;&#xff0c;&#x800c;SLE&#x60a3;&#x8005;&#xff3b;21.14%&#xff08;3 720/17 597&#xff09;&#xff3d;&#x548c;&#x75db;&#x98ce;&#x60a3;&#x8005;&#xff3b;28.73%&#xff08;8 242/28 692&#xff09;&#xff3d;&#x6700;&#x9ad8;&#x3002;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x4ee5;&#x4e19;&#x6c28;&#x9178;&#x8f6c;&#x6c28;&#x9176;&#x5347;&#x9ad8;&#x4e3a;&#x4e3b;&#xff0c;&#x4e14;&#x5927;&#x591a;&#x6570;&#x4e3a;1&#x7ea7;&#xff0c;&#x78b1;&#x6027;&#x78f7;&#x9178;&#x9176;&#x5347;&#x9ad8;&#x7684;&#x6bd4;&#x4f8b;&#x6700;&#x4f4e;&#x3002;&#x670d;&#x7528;&#x4fdd;&#x809d;&#x836f;&#x7269;&#x7684;&#x60a3;&#x8005;&#x4e2d;&#xff0c;&#x809d;&#x529f;&#x80fd;&#x6b63;&#x5e38;&#x6bd4;&#x4f8b;&#x75db;&#x98ce;&#x60a3;&#x8005;&#x6700;&#x4f4e;&#xff3b;7.45%&#xff08;36/483&#xff09;&#xff3d;&#xff0c;&#x4f59;&#x4e3a;21.7%~30.34%&#x3002;RA&#x3001;SLE&#x3001;SS&#x3001;AS&#x3001;&#x75db;&#x98ce;&#x60a3;&#x8005;&#x4e2d;&#xff0c;&#x7537;&#x6027;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x7387;&#x5747;&#x9ad8;&#x4e8e;&#x5973;&#x6027;&#xff3b;RA&#xff1a;13.8%&#xff08;1 368/9 906&#xff09;&#x6bd4;10.3%&#xff08;4 102/39 753&#xff09;&#xff1b;SLE&#xff1a;33.6%&#xff08;479/1 424&#xff09;&#x6bd4;20.0%&#xff08;3 241/16 173&#xff09;&#xff1b;SS&#xff1a;25.4%&#xff08;111/437&#xff09;&#x6bd4;17.6%&#xff08;1 513/8 602&#xff09;&#xff1b;AS&#xff1a;20.1%&#xff08;1 629/8 119&#xff09;&#x6bd4;13.6%&#xff08;434/3 202&#xff09;&#xff1b;&#x75db;&#x98ce;&#xff1a;29.3%&#xff08;8 033/27 394&#xff09;&#x6bd4;16.1%&#xff08;209/1 298&#xff09;&#xff3d;&#x3002;RA&#x3001;SLE&#x3001;AS&#x60a3;&#x8005;&#x4e2d;&#xff0c;&#x5404;&#x5e74;&#x9f84;&#x6bb5;&#x7684;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x7387;&#x76f8;&#x4f3c;&#xff1b;SS&#x60a3;&#x8005;&#x4e2d;&#xff0c;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x7387;&#x968f;&#x5e74;&#x9f84;&#x589e;&#x5927;&#x800c;&#x5347;&#x9ad8;&#xff3b;&lt;40&#x5c81;&#x8005;&#x4e3a;14.9%&#xff08;294/1 979&#xff09;&#xff1b;40~59&#x5c81;&#x8005;&#x4e3a;18.1%&#xff08;858/4 741&#xff09;&#xff1b;&#x2265;60&#x5c81;&#x8005;&#x4e3a;20.4%&#xff08;472/2 319&#xff09;&#xff3d;&#xff1b;&#x75db;&#x98ce;&#x60a3;&#x8005;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x7387;&#x968f;&#x5e74;&#x9f84;&#x589e;&#x5927;&#x800c;&#x964d;&#x4f4e;&#xff3b;&lt;40&#x5c81;&#x8005;&#x4e3a;34.9%&#xff08;4 294/12 320&#xff09;&#xff1b;40~59&#x5c81;&#x8005;&#x4e3a;25.5%&#xff08;2 905/11 398&#xff09;&#xff1b;&#x2265;60&#x5c81;&#x8005;&#x4e3a;21.0%&#xff08;1 042/4 971&#xff09;&#xff3d;&#x3002; <b>&#x7ed3;&#x8bba;&#xff1a;</b> &#x98ce;&#x6e7f;&#x514d;&#x75ab;&#x75c5;&#x60a3;&#x8005;&#x5408;&#x5e76;&#x809d;&#x529f;&#x80fd;&#x5f02;&#x5e38;&#x7684;&#x6bd4;&#x4f8b;&#x8f83;&#x9ad8;&#xff0c;&#x4f46;&#x4fdd;&#x809d;&#x836f;&#x7269;&#x7684;&#x4f7f;&#x7528;&#x7387;&#x4f4e;&#x3002;&#x98ce;&#x6e7f;&#x514d;&#x75ab;&#x75c5;&#x7684;&#x8bca;&#x7597;&#x8fc7;&#x7a0b;&#x4e2d;&#x9700;&#x63d0;&#x9ad8;&#x5bf9;&#x809d;&#x529f;&#x80fd;&#x76d1;&#x6d4b;&#x7684;&#x91cd;&#x89c6;&#xff0c;&#x53ef;&#x8003;&#x8651;&#x9002;&#x65f6;&#x5e94;&#x7528;&#x4fdd;&#x809d;&#x836f;&#x7269;&#xff0c;&#x4f18;&#x5316;&#x4fdd;&#x809d;&#x6cbb;&#x7597;&#x65b9;&#x6848;&#x3002;.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37650184</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112138-20220909-00669</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>